A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas

This study is a platform trial for the evaluation of new drugs or combination of drugs in relapsed or refractory peripheral T-cell lymphomas. The objective of the study is to generate exploratory data on new drugs or combination of drugs to treat refractory/relapse peripheral T-cells lymphoma to better identify the population of interest and design future correct clinical trials. Primary objectives of the different sub-studies : * phase 1 sub-studies: determine the safety and tolerability of escalating doses of the sub-study treatment * phase 2 sub-studies: identify drugs that will improve

Trial Details

NCT ID
NCT07018752
Phase
PHASE1 / PHASE2
Sponsor
The Lymphoma Academic Research Organisation
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • roginolisib
  • golcadomide
  • azacitidine
Locations (sample)
  • Caen, France|49.18585,-0.35912
  • Clermont-Ferrand, France|45.77969,3.08682
  • Créteil, France|48.79266,2.46569
  • Dijon, France|47.31344,5.01391
  • La Tronche, France|45.20507,5.74629

Key Eligibility Criteria

  • For anaplastic large cell lymphoma subjects: failed or ineligible or intolerant to brentuximab vedotin. For extranodal NK/T-cells lymphoma: failed …
  • Additional inclusion criteria specific to Golcaza sub-study:
  • 13\. Subject had local diagnosed (nodal) follicular helper T cell lymphoma according to WHO classification 2022 or ICC 2022 classification based on…
  • angioimmunoblastic type (AITL)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →